^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
...Participants may be diagnosed with EGFR mutated or EGFR wild type NSCLC....
Trial ID:
Source:
Title:
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Excerpt:
...- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation...
Trial ID:
More C2 evidence
Source:
Title:
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Excerpt:
...EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation...
Trial ID:
Source:
Title:
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Un estudio clínico para evaluar la seguridad y la eficacia de la terapia combinada de amivantamab y capmatinib en el cáncer de pulmón no microcítico metastásico irresecable
Excerpt:
...For Phase 2 – Expansion:- Cohort 1A: MET exon 14 skipping mutation (without prior therapy for metastatic disease)- Metastatic NSCLC previously characterized as MET exon 14 skipping mutation positive AND lacking EGFR and ALK mutation, by a local test using a CLIA certified laboratory or an accredited laboratory- Participant must not have received systemic anti-cancer therapy for metastatic NSCLC. ...
Trial ID:
Less C2 evidence
Source:
Title:
BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC)
Published date:
11/28/2023
Excerpt:
Sixty-one patients received amivantamab....In the classical mutation cohort of the 33 evaluable patients, twelve (36.4%) had clinical response and DCR was 48.5%. In the atypical mutation cohort, six of the seven patients (85.7%) had clinical response and DCR was 100%....Our real-world multi-center analysis demonstrated that amivantamab is a potentially effective treatment option for patients with EGFR mutations outside of Exon 20 insertion mutations.
DOI:
10.1016/j.jtho.2023.11.020
Source:
Title:
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Published date:
10/16/2023
Excerpt:
...we present 13 patients who received amivantamab on top of their previous EGFR TKI for disease progression (Group A - common EGFRm+ & Group B - EGFR Exon20+)….The median progression-free survival was 4.7 months in both groups….Incorporating amivantamab to prior EGFR TKI treatment appears to be a feasible option, although osimertinib stands out as the most well-tolerated TKI with clinical efficacy.
Source:
Title:
Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC
Published date:
08/08/2023
Excerpt:
8 had common EGFR mutations (Group A) and 5 EGFR exon 20 (Group B). All group A patients had osimertinib as last line before amivantimab while Group B, 3 patients received mobocertinib, 1 afatinib and 1 poziotinib. Amivantamab was administered on top of previous line in all patients .The objective response rate (ORR) was 75% in group A and 100% in group B.
